CASTLEFORD, England, October 4, 2010 /PRNewswire/ -- We are pleased to announce the launch of Dorzolamide/Timolol 20mg/5mg per ml ophthalmic solution.
It is indicated in the treatment of elevated intra-ocular pressure (IOP) in patients with open-angle glaucoma or pseudo-exfoliative glaucoma when topical beta-blocker monotherapy is not sufficient(1).
It is a generic version of Cosopt(R) from Merck Sharp & Dohme Limited and is available immediately in the award-winning Teva 360 livery, which is designed to aid patient safety, as Dorzolamide/Timolol 20mg/5mg per ml Ophthalmic Solution 5ml in a single pack.
The Teva retail price for the product is GBP9.05.
Kim Innes, Commercial Director at Teva UK Limited said "We are pleased to add this product to our ever-expanding product portfolio - the widest of any UK generics supplier."
To find out more about Teva UK Limited, visit http://www.tevauk.com.
References:
1. Dorzolamide/Timolol Ophthalmic Solution Summary of Product Characteristics
Notes to Editors:
About Teva UK Limited
Teva UK Limited is one of the UK's top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.
About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,250 molecules and a direct presence in 59 countries.
Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone(R), is the number one prescribed treatment for multiple sclerosis. Teva employs over 40,000 people around the world and reached $13.9 billion in net sales in 2009.
Teva UK Ltd
For media enquiries, contact the Teva UK Limited Communications team on +44-(0)1977-628500, or email media.enquiries@tevauk.com.